Antihypertensive Prescriptions over a 10-year Period in a Large Chinese Population
Overview
Authors
Affiliations
Background: International guidelines recommending antihypertensive prescriptions for the management of hypertension have been published in the past decade. Beta-blocker use was discouraged by a significant body of evidence and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) were found more effective among younger patients. This study aims to evaluate the trends in prescription profiles in a large Chinese population because patterns of antihypertensive agent dispensation represent important information for physicians and policymakers.
Methods: From clinical databases consisting of all patient records in the public health-care system of Hong Kong, we examined all antihypertensive prescriptions according to the drug classes (thiazide diuretics, alpha-blockers, beta-blockers, calcium channel blockers (CCBs), ACEIs, ARBs, fixed-dose combinations, and polytherapy (2, ≥3)) between 2001 and 2010. We retrieved >6.3 million prescription episodes for 223,287 patients.
Results: The average age of the patients was 59.9 years (SD = 17.6), and 54.8% were women. According to prescription episodes, the most commonly prescribed medications were beta-blockers (31.7%) and CCBs (29.2%), followed by ACEIs (13.9%), thiazide diuretics (5.0%), and alpha-blockers (4.5%). Between 2001 and 2010, the prescription proportions of beta-blockers decreased from 41.5% to 21.5%, whereas that of ARBs increased from 0.5% to 1.0% (P < 0.001, χ(2) test for trend). It was found that the decline of beta-blockers (71.0% to 35.4%) and increase in ARB prescriptions (0.4% to 1.0%) were particularly marked among younger subjects aged <55 years.
Conclusions: These findings provided information on the prescription patterns of antihypertensive agents in a large Chinese population. It sets a future research direction to study the various reasons influencing these drug class-specific trends.
Management of Hypertension in the Asia-Pacific Region: A Structured Review.
Rahman A, Magno J, Cai J, Han M, Lee H, Nair T Am J Cardiovasc Drugs. 2024; 24(2):141-170.
PMID: 38332411 PMC: 10973088. DOI: 10.1007/s40256-023-00625-1.
Ortega-Montiel J, Montoya A, Soria-Saucedo R, Gallegos-Carrillo K, Ramirez-Palacios P, Salmeron J Adv Pharmacol Pharm Sci. 2023; 2023:5555274.
PMID: 38035129 PMC: 10684324. DOI: 10.1155/2023/5555274.
Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis.
Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J BMC Geriatr. 2022; 22(1):601.
PMID: 35854209 PMC: 9297624. DOI: 10.1186/s12877-022-03279-x.
Wu Y, Cao Y, Song J, Tian Y, Wang M, Li M Medicine (Baltimore). 2019; 98(40):e17411.
PMID: 31577753 PMC: 6783152. DOI: 10.1097/MD.0000000000017411.
Du L, Cheng Z, Zhang Y, Li Y, Mei D J Clin Hypertens (Greenwich). 2018; 20(5):902-907.
PMID: 29700923 PMC: 8030969. DOI: 10.1111/jch.13272.